Foamix Pharmaceuticals Ltd (FOMX) Given Consensus Rating of “Hold” by Brokerages
Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have earned a consensus rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $17.67.
A number of equities analysts recently weighed in on the stock. HC Wainwright set a $12.00 price target on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 4th. Cowen set a $30.00 price target on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Bank of America assumed coverage on shares of Foamix Pharmaceuticals in a research report on Wednesday, December 12th. They set a “buy” rating and a $11.00 price target on the stock.
In other Foamix Pharmaceuticals news, insider Matthew T. Wiley purchased 13,440 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were purchased at an average cost of $3.76 per share, for a total transaction of $50,534.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.30% of the company’s stock.
FOMX opened at $4.03 on Friday. The stock has a market cap of $222.92 million, a P/E ratio of -2.37 and a beta of 1.68. Foamix Pharmaceuticals has a twelve month low of $3.21 and a twelve month high of $7.60.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.